Navigation Links
Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
Date:11/5/2012

By E.J. Mundell
HealthDay Reporter

MONDAY, Nov. 5 (HealthDay News) -- About a quarter of people who experience the dangerous blood clots in the legs or lungs known as venous thromboembolisms (VTEs) develop them for no discernable reason, and most will receive a powerful anti-clotting drug such as warfarin in the months after the clot forms.

But what about longer-term care, to ward off a recurrent clot, or events such as heart attack or stroke? A new study suggests that patients who go on low-dose daily aspirin after they are weaned off more powerful anticoagulants can derive real benefit.

While this study alone could not show a significant effect for aspirin therapy in preventing a recurrent clot for these patients, it did show a significant lowering of overall cardiovascular risk for such complications as heart attack, stroke, major bleeding or death from any cause.

The study was presented Sunday at the American Heart Association's annual meeting in Los Angeles, and was published simultaneously in the New England Journal of Medicine.

The study authors said they saw a "non-significant" trend hinting at aspirin's ability to prevent a second VTE, but the study group was simply too small to push that to statistical significance.

However, they added, when the findings from this study were combined with those of a similar trial called WARFASA, the combined data did show that daily aspirin could prevent recurrent blood clots.

"The essential message of the study that we are presenting today, and combining that with the WARFASA study that was published earlier this year in the NEJM, is that aspirin does have a benefit: about a 30 percent risk reduction of recurrent vein thrombosis, and also about a similar effect in reducing other major vascular events stroke, myocardial infarction [heart attack] and cardiovascular death," said study author Timothy Brighton, a consultant hematologist in Sydney, Australia.

VTEs include sudden, potentially life-threatening clots in the legs (known as deep vein thrombosis, or DVT) and clots that travel to the lungs, called pulmonary embolisms.

As Brighton explained, in about 75 percent of cases, these clots have a known cause injury, surgery or underlying illness, for example. But for the other quarter of patients, the cause is unknown.

More than 800 people with a VTE of uncertain cause were included in the new study. Approximately half were given low-dose (100 milligrams/day) daily aspirin, while the other half received a placebo, after they had completed their initial regimen of a more powerful anticoagulant. The patients were then followed for an average of more than three years.

Brighton noted that patients often cannot continue on anticoagulants such as warfarin indefinitely, because of bleeding risks and inconveniences associated with these drugs.

"The question comes, though, after [discontinuation of initial anti-coagulation therapy], what do you do?" he said.

The answer, from the new study as well as WARFASA, seems to be low-dose daily aspirin. Brighton's group also pointed out that incidents of bleeding were similar for those on low-dose aspirin and placebo, suggesting that aspirin does not raise bleeding risk.

One cardiologist said the study is encouraging for patients. Dr. Stephen Green, associate chairman of the department of cardiology at North Shore University Hospital in Manhasset, N.Y., said that while it's true the trial (on its own) did not find a significant effect of aspirin in reducing VTE recurrence, "the study was positive enough that physicians should consider adding aspirin when stopping warfarin in patients who are reasonable candidates for long-term aspirin."

But he also noted that since the time of the trial, many patients with VTE have now moved from initial warfarin therapy to treatment with newer blood-thinning agents such as Xarelto and Pradaxa.

More study might be needed to assess aspirin's effectiveness in that clinical scenario, he said.

More information

Find out more about deep vein thrombosis at the U.S. National Library of Medicine.

SOURCES: Timothy Brighton, MB, BS, consultant hematologist, Sydney, Australia; Stephen Green, M.D., associate chairman, department of cardiology, North Shore University Hospital, Manhasset, N.Y.; Nov 4, 2012, presentation, American Heart Association annual meeting, Los Angeles; Nov. 4, 2012, New England Journal of Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Daily Aspirin May Bolster Aging Brain, Study Shows
2. BMJ and Daily Telegraphs fake hip exposes failing European device regulation
3. Daily disinfection of isolation rooms reduces contamination of healthcare workers hands
4. For Mild Asthma, Daily Steroids May Not Be Needed, Study Says
5. AAO-HNSF 2012 daily miniseminars highlights
6. AAO-HNSF 2012 new oral research daily highlights
7. Daily Temper Tantrums Not the Norm for Preschoolers: Study
8. Daily Aspirin May Help Fight Prostate Cancer, But Not Breast Cancer
9. Working moms spend less time daily on kids diet, exercise, study finds
10. Daily Aspirin May Cut Cancer Deaths, Another Study Finds
11. Daily aspirin usage associated with lower cancer mortality
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
(Date:2/12/2016)... ... 2016 , ... Each year, the American Physical Therapy Association (APTA) offers a ... Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to attend ... about their chosen field and network with their colleagues. As in years past, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, ... real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... Colorado (PRWEB) , ... February 12, 2016 , ... Vail ... ASC Industry Physician Leaders to Know in 2016 . The list consists of physicians ... nominated physicians to establish this list. , An Ambulatory Surgery Center, also known ...
(Date:2/12/2016)... ... ... For Coast Dental dentist Everet Lake, DDS, the smiles began at dawn. He ... 7 a.m. to volunteer at Friday’s Dentistry from the Heart event in New Port ... hundreds of uninsured and underinsured people receive much-needed dental care. , This was ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ) is pleased to announce the promotion of ... Strategies effective Jan. 23, 2016. To learn ... ... ... ...
(Date:2/12/2016)...  SI-BONE, Inc., a medical device company that pioneered the use ... surgical (MIS) device indicated for fusion for certain disorders of the ... Medicare Administrative Contractor (MAC) covering the states of Connecticut ... , Massachusetts , Minnesota , ... , Rhode Island , Vermont ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. ... Macrogen, Inc. today announced they will form a ... for precision medicine in cancer. The goal of ... digital-sorting technology with Macrogen,s high-throughput Next Generation Sequencing ... the Clinical Laboratory Improvement Amendments (CLIA) of 1988 ...
Breaking Medicine Technology: